Eupraxia Pharmaceuticals Inc.

TSX:EPRX Stock Report

Market Cap: CA$163.9m

Eupraxia Pharmaceuticals Valuation

Is EPRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EPRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EPRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EPRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EPRX?

Key metric: As EPRX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for EPRX. This is calculated by dividing EPRX's market cap by their current book value.
What is EPRX's PB Ratio?
PB Ratio13.5x
BookUS$9.52m
Market CapUS$117.20m

Price to Book Ratio vs Peers

How does EPRX's PB Ratio compare to its peers?

The above table shows the PB ratio for EPRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.7x
MDNA Medicenna Therapeutics
5.8x60.2%CA$126.6m
ONC Oncolytics Biotech
11.9x37.5%CA$114.1m
COV Covalon Technologies
4.9xn/aCA$109.6m
MSCL Satellos Bioscience
4.3x-15.1%CA$86.2m
EPRX Eupraxia Pharmaceuticals
13.5xn/aCA$163.9m

Price-To-Book vs Peers: EPRX is expensive based on its Price-To-Book Ratio (13.5x) compared to the peer average (6.7x).

Price to Book Ratio vs Industry

How does EPRX's PB Ratio compare vs other companies in the CA Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
QPT Quest PharmaTech
0.3xn/aUS$4.23m
CURE.X Biocure Technology
0.2xn/aUS$224.11k
No more companies available in this PB range
EPRX 13.5xIndustry Avg. 2.6xNo. of Companies3PB01.22.43.64.86+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: EPRX is expensive based on its Price-To-Book Ratio (13.5x) compared to the Canadian Biotechs industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is EPRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EPRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio13.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate EPRX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EPRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$5.03
CA$12.25
+143.5%
27.5%CA$16.50CA$8.25n/a3
Nov ’25CA$4.30
CA$13.75
+219.8%
28.3%CA$16.50CA$8.25n/a3
Oct ’25CA$3.50
CA$13.75
+292.9%
28.3%CA$16.50CA$8.25n/a3
Sep ’25CA$3.43
CA$15.13
+341.2%
12.8%CA$16.50CA$12.40n/a3
Aug ’25CA$3.83
CA$15.13
+295.1%
12.8%CA$16.50CA$12.40n/a3
Jul ’25CA$3.50
CA$15.13
+332.4%
12.8%CA$16.50CA$12.40n/a3
Jun ’25CA$3.65
CA$14.45
+295.9%
14.2%CA$16.50CA$12.40n/a2
May ’25CA$3.69
CA$14.45
+291.6%
14.2%CA$16.50CA$12.40n/a2
Apr ’25CA$4.08
CA$15.75
+286.0%
4.8%CA$16.50CA$15.00n/a2
Mar ’25CA$6.27
CA$17.00
+171.1%
11.8%CA$19.00CA$15.00n/a2
Feb ’25CA$5.74
CA$17.00
+196.2%
11.8%CA$19.00CA$15.00n/a2
Jan ’25CA$5.37
CA$15.08
+180.9%
15.6%CA$18.00CA$12.25n/a3
Dec ’24CA$5.60
CA$15.08
+169.3%
15.6%CA$18.00CA$12.25n/a3
Nov ’24CA$5.15
CA$15.08
+192.9%
15.6%CA$18.00CA$12.25CA$4.303
Oct ’24CA$6.90
CA$15.08
+118.6%
15.6%CA$18.00CA$12.25CA$3.503
Sep ’24CA$7.96
CA$14.75
+85.3%
13.2%CA$17.00CA$12.25CA$3.433
Aug ’24CA$7.40
CA$18.33
+147.7%
27.2%CA$25.00CA$13.00CA$3.833
Jul ’24CA$8.65
CA$18.33
+111.9%
27.2%CA$25.00CA$13.00CA$3.503
Jun ’24CA$7.00
CA$10.65
+52.1%
3.3%CA$11.00CA$10.30CA$3.652
May ’24CA$6.25
CA$9.02
+44.3%
25.8%CA$11.00CA$5.75CA$3.693
Apr ’24CA$4.23
CA$9.02
+113.2%
25.8%CA$11.00CA$5.75CA$4.083
Mar ’24CA$4.25
CA$9.02
+112.2%
25.8%CA$11.00CA$5.75CA$6.273
Feb ’24CA$3.95
CA$8.35
+111.4%
22.9%CA$10.30CA$5.75CA$5.743
Jan ’24CA$3.65
CA$7.38
+102.1%
22.0%CA$9.00CA$5.75CA$5.372
Dec ’23CA$3.96
CA$7.38
+86.2%
22.0%CA$9.00CA$5.75CA$5.602
Nov ’23CA$4.14
CA$7.75
+87.2%
16.1%CA$9.00CA$6.50CA$5.152

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.15

7D

5.4%

1Y

40.5%

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.32

7D

-12.8%

1Y

-60.6%

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.50

7D

7.6%

1Y

-44.2%